Roche Expected To File Second Anti-Generic Suit In India
This article was originally published in PharmAsia News
Roche is stepping up its legal fight against India's Cipla over the latter's attempts to market a generic of Valcyte (valganciclovir) for treating HIV/AIDS infections. Roche is expected to intensify the fight by filing in the Madras high court, adding to its legal efforts against Cipla. Another suit already has been filed in the Delhi high court, seeking an injunction against Cipla on grounds its generic infringes on the patent for Tarceva (erlotinib), Roche's anti-cancer drug. The Valcyte suit is expected to be filed in the Madras court because it was patented in the Chennai patent office. (Click here for more
You may also be interested in...
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.
But the agency chose to fund only a small fraction of them, in part because of its hiring ability, and in part because all those employees would have cost an additional $98.7m in user fee revenue.
Legal experts say the EU already prohibits cosmetic use of CBD sourced from hemp flowers, and it now appears that food supplement use could be held to the same standard. The World Health Organization has recommended changes to the half-century-old international treaty governing narcotic controls, which could help to resolve the situation, but there are reports of UN pushback.